Thematic review series: Systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: A global approach to lipid analysis in biological systems

Journal of Lipid Research

Volumn 47, Issue 10, 2006, Pages 2101-2111

  Watson, Andrew D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Eicosanoids; Inflammation; Lipid peroxidation; Mass spectrometry

Indexed keywords

BIOLOGICAL MARKER; LIPID;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; DIABETES MELLITUS; EXTRACTION; GENOMICS; IONIZATION; LIPID ANALYSIS; LIPID OXIDATION; MASS SPECTROMETRY; METABOLOMICS; OBESITY; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SEPARATION TECHNIQUE; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; LIPID METABOLISM; MASS SPECTROMETRY; METABOLIC DISEASES; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

EID: 33845564160     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R600022-JLR200     Document Type: Review

References (111)

1. Hood, L., J. R. Heath, M. E. Phelps, and B. Lin. 2004. Systems biology and new technologies enable predictive and preventative medicine. Science. 306: 640-643.
2. Nicholson, J. K., and I. D. Wilson. 2003. Understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat. Rev. Drug Discov. 2: 668-676.
3. Kitano, H. 2002. Systems biology: a brief overview. Science. 295: 1662-1664.
4. Oda, K., and H. Kitano. 2006. A comprehensive map of the toll-like receptor signaling network. Mol. Syst. Biol. 2: E1-E20.
5. Oda, K., Y. Matsuoka, A. Funahashi, and H. Kitano. 2005. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol. 1: E1-E17.
6. Domon, B., and R. Aebersold. 2006. Mass spectrometry and protein analysis. Science. 312: 212-217.
7. Sickmann, A., M. Mreyen, and H. E. Meyer. 2003. Mass spectrometry - a key technology in proteome research. Adv. Biochem. Eng. Biotechnol. 83: 141-176.
8. Goodacre, R., S. Vaidyanathan, W. B. Dunn, G. G. Harrigan, and D. B. Kell. 2004. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol. 22: 245-252.
9. Hoefnagel, M. H. N., M. J. C. Starrenburg, D. E. Martens, J. Hugenholtz, M. Kleerebezem, I. I. Van Swam, R. Bongers, H. V. Westerhoff, and J. L. Snoep. 2002. Metabolic engineering of lactic acid bacteria, the combined approach: inetic modelling, metabolic control and experimental analysis. Microbiol. 148: 1003-1013.
10. Sillerud, L. O., R. K. Yu, and D. E. Schafer. 1982. Assignment of the carbon-13 nuclear magnetic resonance spectra of gangliosides GM4, GM3, GM2, GM1, GD1a, GD1b, AND GT1b. Biochemistry. 21: 1260-1271.
11. Fahy, E., S. Subramaniam, H. A. Brown, C. K. Glass, A. H. Merrill, Jr., R. C. Murphy, C. R. H. Raetz, D. W. Russell, Y. Seyama, W. Shaw, et al. 2005. A comprehensive classification system for lipids. J. Lipid Res. 46: 839-862.
12. Israelachvili, J. N., D. J. Mitchell, and B. W. Nonham. 1977. Theory of self-assembly of lipid bilayers and vesicles. Biochim. Biophys. Acta. 470: 185-201.
13. Chernomordik, L. 1996. Non-bilayer lipids and biological fusion intermediates. Chem. Phys. Lipids. 81: 203-213.
14. Tate, M. W., E. F. Eikenberry, D. C. Turner, E. Shyamsunder, and S. M. Gruner. 1991. Nonbilayer phases of membrane lipids. Chem. Phys. Lipids. 57: 147-164.
15. Singer, S. J., and G. L. Nicholson. 1972. The fluid mosaic model of the structure of cell membranes. Science. 175: 720-731.
16. Varma, R., and S. Mayor. 1998. GPI-anchored proteins are organized in submicron domains at the cell surface. Nature. 394: 798-801.
17. Mineo, C., G. L. James, E. J. Smart, and R. G. W. Anderson. 1996. Localization of epidermal growth factor-stimulated Ras/Raf-1 interaction to caveolae membrane. J. Biol. Chem. 271: 11930-11935.
18. Shenoy-Scaria, A. M., D. J. Dietzen, J. Kwong, D. C. Link, and D. M. Lublin. 1994. Cysteine3 of Src family protein tyrosine kinase determines palmitoylation and localization in caveolae. J. Cell Biol. 126: 353-363.
19. Hooper, N. M. 1999. Detergent-insoluble glycosphingolipid/cholesterol- rich membrane domains, lipid rafts and caveolae (review). Mol. Membr. Biol. 16: 145-156.
20. Hla, T. 2005. Genomic insights into mediator lipidomics. Prostaglandins Other Lipid Mediat. 77: 197-209.
21. Zarini, S., M. A. Gijon, G. Folco, and R. C. Murphy. 2006. Effect of arachidonic acid reacylation on leukotriene biosynthesis in human neutrophils stimulated with granulocyte-macrophage colony stimulating factor and formyl-methionyl-leucyl-phenylalanine. J. Biol. Chem. 281: 10134-10142.
22. FitzGerald, G. A. 2003. Cox-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov. 2: 879-890.
23. FitzGerald, G. A., and C. Patrono. 2001. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345: 433-442.
24. Radmark, O. 2002. Arachidonate 5-lipoxygenase. Prostaglandins Other Lipid Mediat. 68-69: 211-234.
25. Samuelsson, B. 1983. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 220: 568-575.
26. Samuelsson, B., S. E. Dahlen, J. A. Lindgren, C. A. Rouzer, and C. N. Serhan. 1987. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 237: 1171-1176.
27. Serhan, C. N., and K-A. Sheppard. 1990. Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J. Clin. Invest. 85: 772-780.
28. Olkkonen, V. M., and M. Lehto. 2004. Oxysterols and oxysterol binding proteins: role in lipid metabolism and atherosclerosis. Ann. Med. 36: 562-572.
29. Brown, A. J., and W. Jessup. 1999. Oxysterols and atherosclerosis. Atherosclerosis. 142: 1-28.
30. Smith, L. L., and B. H. Johnson. 1989. Biological activities of oxysterols. Free Radic. Biol. Med. 7: 285-332.
31. Hodis, H. N., D. W. Crawford, and A. Sevanian. 1991. Cholesterol feeding increases plasma and aortic tissue cholesterol oxide levels in parallel: further evidence for the role of cholesterol oxidation in atherosclerosis. Atherosclerosis. 89: 117-126.
32. Tontonoz, P., and D. J. Mangelsdorf. 2003. Liver X receptor signaling pathways in cardiovascular disease. Mol. Endocrinol. 17: 985-993.
33. Tangirala, R. K., E. D. Bischoff, S. B. Joseph, B. L. Wagner, R. Walczak, B. A. Laffitte, C. L. Daige, D. Thomas, R. A. Heyman, D. J. Mangelsdorf, et al. 2002. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl. Acad. Sci. USA. 99: 11896-11901.
34. Benveniste, J., P. M. Henson, and C. G. Cochrane. 1972. Leukocyte-dependent histamine release from rabbit platelets. J. Exp. Med. 136: 1356-1377.
35. Demopoulos, C. A., R. N. Pinckard, and D. J. Hanahan. 1979. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3- phosphorylcholine as the active component (a new class of lipid chemical mediators). J. Biol. Chem. 254: 9355-9358.
36. Hanahan, D. J. 1986. Platelet activating factor: a biologically active phosphoglyceride. Annu. Rev. Biochem. 55: 483-509.
37. Zimmerman, G. A., T. M. McIntyre, S. M. Prescott, and D. M. Stafforini. 2002. The platelet-activating factor signalling system and its regulation in syndromes of inflammation and thrombosis. Crit. Care Med. 30 (Suppl.): 294-301.
38. Merrill, A. H., Jr., E. M. Schmelz, D. L. Dillehay, S. Spiegel, J. A. Shayman, J. J. Schroeder, R. T. Riley, K. A. Voss, and E. Wang. 1997. Sphingolipids-the enigmatic lipid class: biochemistry, physiology, and pathophysiology. Toxicol. Appl. Pharmacol. 142: 208-225.
39. Gomez-Munoz, A. 2006. Ceramide 1-phosphate/ceramide, a switch between life and death. Biochim. Biophys. Acta. Epub ahead of print. May 19, 2006. doi:10.1016/j.bbamem.2006.05.011.
40. Spiegel, S., and A. H. Merrill, Jr. 1996. Sphingolipid metabolism and cell growth regulation. FASEB J. 10: 1388-1397.
41. Ogretmen, B., and Y. A. Hannun. 2004. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer. 4: 604-616.
42. Ishii, I., N. Fukushima, X. Ye, and J. Chun. 2004. Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem. 73: 321-354.
43. Ledeen, R. W., and G. Wu. 2006. Sphingolipids of the nucleus and their role in nuclear signaling. Biochim. Biophys. Acta. 1761: 588-598.
44. Pyne, S., K-C. Kong, and P. I. Darroch. 2004. Lysophosphatidic acid and sphingosine 1-phosphate biology: the role of lipid phosphate phosphatases. Semin. Cell Dev. Biol. 15: 491-501.
45. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37: 911-917.
46. Folch, J., M. Lees, and G. H. Sloane-Stanley. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226: 497-509.
47. Saunders, R. D., and L. A. Horrocks. 1984. Simultaneous extraction and preparation for high-performance liquid chromatography of prostaglandins and phospholipids. Anal. Biochem. 143: 71-75.
48. Tsvet, M. A. 1906. Physical chemical studies on chlorophyll adsorptions. Ber. Dtsch. Bot. Ges. 24: 316-323.
49. Izmailov, N. A., and M. S. Shraiber. 1938. Farmatsiya (Moscow). 3: 1-7.
50. Bennett, R. D., and E. Heftmann. 1962. Thin-layer chromatography of sterols. J. Chromatogr. 9: 295-300.
51. Michalec, C., M. Sulc, and J. Mestan. 1962. Analysis of cholesteryl esters and triglycerides by thin-layer chromatography. Nature. 193: 63-64.
52. Ruggieri, S. 1962. Separation of the methyl esters of fatty acids by thin layer chromatography. Nature. 193: 1282-1283.
53. Kaluzny, M. A., L. A. Duncan, M. V. Merritt, and D. E. Epps. 1985. Rapid separation of lipid classes in high yield and purity using bonded phase columns. J. Lipid Res. 26: 135-140.
54. Powell, W. S. 1980. Rapid extraction of oxygenated metabolites of arachidonic acid from biological samples using octadecylsilyl silica. Prostaglandins. 20: 947-957.
55. Powell, W. S. 1982. Rapid extraction of arachidonic acid metabolites from biological samples using octadecylsilyl silica. Methods Enzymol. 86: 467-477.
56. Hawkins, D. J., H. Huhn, E. H. Petty, and A. R. Brash. 1988. Resolution of enantiomers of hydroxyeicosatetraenoiate derivatives by chiral phase high-pressure liquid chromatography. Anal. Biochem. 173: 456-462.
57. Hughes, M. A., and A. R. Brash. 1991. Investigation of the mechanism of biosythesis of 8-hydroxyeicosatetraenoic acid in mouse skin. Biochim. Biophys. Acta. 1081: 347-354.
58. Lesnefsky, E. J., M. S. K. Stoll, P. E. Minkler, and C. L. Hoppel. 2000. Separation and quantitation of phospholipids and lysophospholipids by high-performance liquid chromatography. Anal. Biochem. 285: 246-254.
59. Malavolta, M., F. Bocci, E. Boselli, and N. G. Frega. 2004. Normal phase liquid chromatography-electrospray ionization tandem mass spectrometry analysis of phospholipid molecular species in blood mononuclear cells: application to cystic fibrosis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 810: 173-186.
60. McHowat, J., J. H. Jones, and M. H. Creer. 1997. Gradient elution reversed-phase chromatographic isolation of individual glycerophospholipid molecular species. J. Chromatogr. B Biomed. Sci. Appl. 702: 21-32.
61. Nakamura, T., D. L. Bratton, and R. C. Murphy. 1997. Analysis of epoxyeicosatrienoic and monohydroxyeicosatetraenoic acids esterified to phospholipids in human red blood cells by electrospray tandem mass spectrometry. J. Mass Spectrom. 32: 888-896.
62. Dole, M., L. L. Mack, R. L. Hines, R. C. Mobley, L. D. Ferguson, and M. B. Alice. 1968. Molecular beams of macroions. J. Chem. Phys. 49: 2241-2249.
63. Carroll, D. I., I. Dzidic, R. N. Stillwell, K. D. Haegele, and E. C. Horning. 1975. Atmospheric pressure ionization mass spectrometry: corona discharge ion source for use in liquid chromatography-mass spectrometry-computer analytical system. Anal. Biochem. 47: 2369-2373.
64. Byrdwell, W. C. 2001. Atmospheric pressure chemical ionization mass spectrometry for analysis of lipids. Lipids. 36: 327-346.
65. Cai, S. S., and J. A. Syage. 2006. Comparison of atmospheric pressure photoionization, atmospheric pressure chemical ionization, and electrospray ionization mass spectrometry for analysis of lipids. Anal. Chem. 78: 1191-1199.
66. Cooks, R. G., Z. Ouyang, Z. Takats, and J. M. Wiseman. 2006. Ambient mass spectrometry. Science. 311: 1566-1570.
67. van Kuijk, F. J. G. M., D. W. Thomas, R. J. Stephens, and E. A. Dratz. 1985. Gas chromatography-mass spectrometry method for determination of phospholipid peroxides; I. Transesterification to form methyl esters. J. Free Radic. Biol. Med. 1: 215-225.
68. Hall, L. M., and R. C. Murphy. 1998. Analysis of stable oxidized molecular species of glycerophospholipids following treatment of red blood cell ghosts with t-butylhydroperoxide. Anal. Biochem. 258: 184-194.
69. Pulfer, M., and R. C. Murphy. 2003. Electrospray mass spectrometry of phospholipids. Mass Spectrom. Rev. 22: 332-364.
70. Kerwin, J. L., A. M. Wiens, and L. H. Ericsson. 1996. Identification of fatty acids by electrospray mass spectrometry and tandem mass spectrometry. J. Mass Spectrom. 31: 184-192.
71. Watson, A. D., N. Leitinger, M. Navab, K. F. Faull, S. Horkko, J. L. Witztum, W. Palinski, D. Schwenke, R. G. Salomon, W. Sha, et al. 1997. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272: 13597-13607.
72. Hsu, F. F., and J. Turk. 2000. Characterization of phosphatidylinositol, phosphatidylinositol-4-phosphate, and phosphatidylinositol-4,5-bisphosphate by electrospray ionization tandem mass spectrometry: a mechanistic study. J. Am. Soc. Mass Spectrom. 11: 986-999.
73. Larson, A., S. Uran, P. B. Jacobsen, and T. Skotland. 2001. Collision-induced dissociation of glycero phospholipids using electrospray ion-trap mass spectrometry. Rapid Commun. Mass Spectrom. 15: 2393-2398.
74. Han, X., and R. W. Gross. 1994. Electrospray ionization mass spectroscopic analysis of human erythrocyte plasma membrane phospholipids. Proc. Natl. Acad. Sci. USA. 91: 10635-10639.
75. Han, X., K. Yang, J. Yang, H. Cheng, and R. W. Gross. 2006. Shotgun lipidomics of cardiolipin molecular species in lipid extracts of biological samples. J. Lipid Res. 47: 864-879.
76. Kagan, V. E., V. A. Tyurin, J. Jiang, Y. Y. Tyurina, V. B. Ritov, A. A. Amoscato, A. N. Osipov, N. A. Belikova, A. A. Kapralov, V. Kini, et al. 2005. Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors. Nat. Chem. Biol. 1: 223-232.
77. Milne, S. B., P. T. Ivanova, D. DeCamp, R. C. Hsueh, and H. A. Brown. 2005. A targeted mass spectrometric analysis of phosphatidylinositol phosphate species. J. Lipid Res. 46: 1796-1802.
78. Guan, X. L., X. He, W-Y. Ong, W. K. Yeo, G. Shui, and M. R. Wenk. 2006. Non-targeted profiling of lipids during kainate-induced neuronal injury. FASEB J. 20: 1152-1161.
79. Lee, S. H., M. V. Williams, R. N. DuBois, and I. A. Blair. 2003. Targeted lipidomics using electron capture atmospheric pressure chemical ionization mass spectrometry. Rapid Commun. Mass Spectrom. 17: 2168-2176.
80. Ivanova, P. T., S. B. Milne, J. S. Forrester, and H. A. Brown. 2004. Lipid arrays: new tools in the understanding of membrane dynamics and lipid signaling. Mol. Interv. 4: 86-96.
81. Milne, S., P. Ivanova, J. Forrester, and H. Alex Brown. 2006. Lipidomics: an analysis of cellular lipids by ESI-MS. Methods. 39: 92-103.
82. - with unsaturated fatty acids. J. Biol. Chem. 258: 4759-4761.
83. Porter, N. A., S. E. Caldwell, and K. A. Mills. 1995. Mechanisms of free radical oxidation of unsaturated lipids. Lipids. 30: 277-290.
84. Berliner, J. A., N. Leitinger, A. D. Watson, J. Huber, A. M. Fogelman, and M. Navab. 1997. Oxidized lipids in atherogenesis: formation, destruction and action. Thromb. Haemost. 78: 1-5.
85. Chisolm, G. M., and D. Steinberg. 2000. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic. Biol. Med. 18: 1815-1826.
86. Malle, E., G. Marsche, J. Arnhold, and M. J. Davies. 2006. Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim. Biophys. Acta. 1761: 392-415.
87. Petursdottir, A. L., S. A. Farr, J. E. Morley, W. A. Banks, and G. V. Skuladottir. Lipid peroxidation in brain during aging in the senescence-accelerated mouse (SAM). Neurobiol. Aging. Epub ahead of print. July 14, 2006; doi:10.1016/j.neurobiolaging.2006.05.033.
88. Pyne-Geithman, G. J., C. J. Morgan, K. Wagner, E. M. Dulaney, J. Carrozzella, D. S. Kanter, M. Zuccarello, and J. F. Clark. 2005. Bilirubin production and oxidation in CSF of patients with cerebral vasospasm after subarachnoid hemorrhage. J. Cereb. Blood Flow Metab. 25: 1070-1077.
89. Awad, J. A., L. J. Roberts, R. F. Burk, and J. D. Morrow. 1996. Isoprostanes - prostaglandin-like compounds formed in vivo independently of cyclooxygenase: use as clinical indicators of oxidant damage. Gastroenterol. Clin. North Am. 25: 409-427.
90. Morrow, J. D., and L. J. Roberts. 1996. The isoprostanes: current knowledge and directions for future research. Biochem. Pharmacol. 51: 1-9.
91. Montuschi, P., P. J. Barnes, and L. J. Roberts II. 2004. Isoprostanes: markers and mediators of oxidative stress. FASEB J. 18: 1791-1800.
92. Fam, S. S., and J. D. Morrow. 2003. The isoprostanes: unique products of arachidonic acid oxidation - a review. Curr. Med. Chem. 10: 1723-1740.
93. Morrow, J. D. 2000. The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab. Rev. 32: 377-385.
94. Morrow, J. D., and L. J. Roberts II. 1998. Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol. 300: 3-12.
95. Waugh, R. J., J. D. Morrow, L. J. Roberts II, and R. C. Murphy. 1997. Identification and relative quantitation of F2-isoprostane regioisomers formed in vivo in the rat. Free Radic. Biol. Med. 23: 943-954.
96. Davi, G., G. Ciabattoni, A. Consoli, A. Mezzetti, A. Falco, S. Santarone, E. Pennese, E. Vitacolonna, T. Bucciarelli, F. Costantini, et al. 1999. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 99: 224-229.
97. Pratico, D., V. M-Y. Lee, J. Q. Trojanowski, J. Rokach, and G. A. Fitzgerald. 1998. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 12: 1777-1783.
98. Morrow, J. D., B. Frei, A. W. Longmire, J. M. Gaziano, S. M. Lynch, Y. Shyr, W. E. Strauss, J. A. Oates, and L. J. Roberts. 1995. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N. Engl. J. Med. 332: 1198-1203.
99. Handelman, G. J., M. F. Walter, R. Adhikarla, J. Gross, G. E. Dallal, N. W. Levin, and J. B. Blumberg. 2001. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int. 59: 1960-1966.
100. Polidori, M. C., D. Pratico, K. Savino, J. Rokach, W. Stahl, and P. Mecocci. 2004. Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. J. Card. Fail. 10: 334-338.
101. Pratico, D., L. Iuliano, A. Mauriello, L. Spagnoli, J. A. Lawson, J. Maclouf, F. Violi, and G. A. FitzGerald. 1997. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J. Clin. Invest. 100: 2028-2034.
102. Morrow, J. D. 2005. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler. Thromb. Vasc. Biol. 25: 279-286.
103. Berliner, J. A., and A. D. Watson. 2005. A role for oxidized phospholipids in atherosclerosis. N. Engl. J. Med. 353: 9-11.
104. Berliner, J. A., G. Subbanagounder, N. Leitinger, A. D. Watson, and D. Vora. 2001. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc. Med. 11: 142-147.
105. Watson, A. D., G. Subbanagounder, D. S. Welsbie, K. F. Faull, M. Navab, M. E. Jung, A. M. Fogelman, and J. A. Berliner. 1999. Structural identification of a novel pro-inflammatory epoxyisoprostane phospholipid in mildly oxidized low density lipoprotein. J. Biol. Chem. 274: 24787-24798.
106. Podrez, E. A., E. Poliakov, Z. Shen, R. Zhang, Y. Deng, M. Sun, P. J. Finton, L. Shan, B. Gugiu, P. L. Fox, et al. 2002. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J. Biol. Chem. 277: 38503-38516.
107. Binder, C. J., P. X. Shaw, M-K. Chang, A. Boullier, K. Hartvigsen, S. Horkko, Y. I. Miller, D. A. Woelkers, M. Corr, and J. L. Witztum. 2005. Thematic review series: the immune system and atherogenesis. The role of natural antibodies in atherogenesis. J. Lipid Res. 46: 1353-1363.
108. Hazen, S. L., and G. M. Chisolm. 2002. Oxidized phosphatidylcholines: pattern recognition ligands for multiple pathways of the innate immune response. Proc. Natl. Acad. Sci. USA. 99: 12515-12517.
109. Tsimikas, S., S. Kiechl, J. Willeit, M. Mayr, E. R. Miller, F. Kronenberg, Q. Xu, C. Bergmark, S. Weger, F. Oberhollenzer, et al. 2006. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J. Am. Coll. Cardiol. 47: 2219-2228.
110. Tsimikas, S., E. S. Brilakis, E. R. Miller, J. P. McConnell, R. J. Lennon, K. S. Kornman, J. L. Witztum, and P. B. Berger. 2005. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 353: 46-57.
111. Tsimikas, S., H. K. Lau, K-R. Han, B. Shortal, E. R. Miller, A. Segev, L. K. Curtiss, J. L. Witztum, and B. H. Strauss. 2004. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation. 109: 3164-3170.